{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T02:33:14Z","timestamp":1777948394231,"version":"3.51.4"},"reference-count":111,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012729","name":"Case Western Reserve University Clinical and Translational Science Collaborative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012729","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institutes of Health National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010962","name":"Institut des Sciences du Cerveau de Toulouse","doi-asserted-by":"publisher","award":["80,86"],"award-info":[{"award-number":["80,86"]}],"id":[{"id":"10.13039\/501100010962","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010962","name":"Institut des Sciences du Cerveau de Toulouse","doi-asserted-by":"publisher","award":["41\\u201344"],"award-info":[{"award-number":["41\\u201344"]}],"id":[{"id":"10.13039\/501100010962","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010962","name":"Institut des Sciences du Cerveau de Toulouse","doi-asserted-by":"publisher","award":["59\\u201362"],"award-info":[{"award-number":["59\\u201362"]}],"id":[{"id":"10.13039\/501100010962","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010962","name":"Institut des Sciences du Cerveau de Toulouse","doi-asserted-by":"publisher","award":["50,51"],"award-info":[{"award-number":["50,51"]}],"id":[{"id":"10.13039\/501100010962","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010962","name":"Institut des Sciences du Cerveau de Toulouse","doi-asserted-by":"publisher","award":["NCT02866721"],"award-info":[{"award-number":["NCT02866721"]}],"id":[{"id":"10.13039\/501100010962","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010962","name":"Institut des Sciences du Cerveau de Toulouse","doi-asserted-by":"publisher","award":["52\\u201354"],"award-info":[{"award-number":["52\\u201354"]}],"id":[{"id":"10.13039\/501100010962","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010962","name":"Institut des Sciences du Cerveau de Toulouse","doi-asserted-by":"publisher","award":["88\\u201390"],"award-info":[{"award-number":["88\\u201390"]}],"id":[{"id":"10.13039\/501100010962","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019408","name":"The Marcus Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019408","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.beha.2025.101602","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T12:10:18Z","timestamp":1741349418000},"page":"101602","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Human mesenchymal stem cell therapy: Potential advances for reducing cystic fibrosis infection and organ inflammation"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9698-9113","authenticated-orcid":false,"given":"Tracey L.","family":"Bonfield","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hillard M.","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.beha.2025.101602_bib1","first-page":"589","article-title":"The changing epidemiology of cystic fibrosis: incidence, survival and impact of the CFTRGene discovery","volume":"11","author":"Scotet","year":"2020","journal-title":"Genes. MDPI AG"},{"issue":"3","key":"10.1016\/j.beha.2025.101602_bib2","first-page":"183","article-title":"Progression of cystic fibrosis lung disease from childhood to adulthood: neutrophils, neutrophil extracellular trap (NET) formation, and NET degradation","volume":"10","author":"Khan","year":"2019","journal-title":"Genes. MDPI AG"},{"issue":"11","key":"10.1016\/j.beha.2025.101602_bib3","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.3390\/cells10112844","article-title":"Cftr protein: not just a chloride channel? Vol. 10, Cells. MDPI","volume":"10","author":"Hanssens","year":"2021","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.beha.2025.101602_bib4","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1164\/rccm.201404-0703OC","article-title":"Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in g551d-mediated cystic fibrosis","volume":"190","author":"Rowe","year":"2014","journal-title":"Am J Respir Crit Care Med [Internet]"},{"issue":"1","key":"10.1016\/j.beha.2025.101602_bib5","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1164\/rccm.201701-0134OC","article-title":"Airway mucosal host defense is key to genomic regulation of cystic fibrosis lung disease severity","volume":"197","author":"Polineni","year":"2018","journal-title":"Am J Respir Crit Care Med [Internet]"},{"issue":"1","key":"10.1016\/j.beha.2025.101602_bib6","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jcf.2018.05.013","article-title":"AGTR2 absence or antagonism prevents cystic fibrosis pulmonary manifestations","volume":"18","author":"Darrah","year":"2019","journal-title":"J Cyst Fibros [Internet]"},{"issue":"8","key":"10.1016\/j.beha.2025.101602_bib7","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1039\/C6MB00240D","article-title":"Molecular and genetic inflammation networks in major human diseases","volume":"12","author":"Zhao","year":"2016","journal-title":"Mol Biosyst"},{"key":"10.1016\/j.beha.2025.101602_bib8","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1146\/annurev.genom.6.080604.162254","article-title":"Modifier genetics: cystic fibrosis","volume":"6","author":"Cutting","year":"2005","journal-title":"Annu Rev Genom Hum Genet"},{"issue":"1","key":"10.1016\/j.beha.2025.101602_bib9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13148-016-0300-8","article-title":"DNA methylation at modifier genes of lung disease severity is altered in cystic fibrosis","volume":"9","author":"Magalh\u00e3es","year":"2017","journal-title":"Clin Epigenetics [Internet]"},{"issue":"4","key":"10.1016\/j.beha.2025.101602_bib10","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jcf.2017.06.001","article-title":"Impaired innate immune cells in cystic fibrosis: is it really a surprise?","volume":"16","author":"Bonfield","year":"2017","journal-title":"J Cyst Fibros [Internet]"},{"issue":"1","key":"10.1016\/j.beha.2025.101602_bib11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ccm.2015.11.010","article-title":"Innate and adaptive immunity in cystic fibrosis","volume":"37","author":"Bruscia","year":"2016","journal-title":"Clin Chest Med [Internet]"},{"key":"10.1016\/j.beha.2025.101602_bib12","volume":"vol. 12","author":"K\u00fcnzi","year":"2021"},{"issue":"173","key":"10.1016\/j.beha.2025.101602_bib13","article-title":"Neutrophil serine proteases in cystic fibrosis: role in disease pathogenesis and rationale as a therapeutic target","volume":"33","author":"Mall","year":"2024","journal-title":"33, European respiratory review : an official journal of the European Respiratory Society"},{"issue":"10","key":"10.1016\/j.beha.2025.101602_bib14","first-page":"1966","article-title":"Lung inflammatory genes in cystic fibrosis and their relevance to cystic fibrosis transmembrane conductance regulator modulator therapies","volume":"14","author":"Carbone","year":"2023","journal-title":"Genes. Multidisciplinary Digital Publishing Institute (MDPI)"},{"issue":"3","key":"10.1016\/j.beha.2025.101602_bib15","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/jleuko\/qiad139","article-title":"Aberrant immune programming in neutrophils in cystic fibrosis","volume":"115","author":"Hu","year":"2024","journal-title":"J Leukoc Biol"},{"issue":"1","key":"10.1016\/j.beha.2025.101602_bib16","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2019","journal-title":"Lancet Respir Med [Internet]"},{"issue":"6","key":"10.1016\/j.beha.2025.101602_bib17","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.152186","article-title":"CFTR-mediated monocyte\/macrophage dysfunction revealed by cystic fibrosis proband-parent comparisons","volume":"7","author":"Zhang","year":"2022","journal-title":"JCI Insight"},{"issue":"3","key":"10.1016\/j.beha.2025.101602_bib18","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jcf.2015.05.008","article-title":"Streptococcus pneumoniae oropharyngeal colonization in children and adolescents with cystic fibrosis","volume":"15","author":"Esposito","year":"2016","journal-title":"J Cyst Fibros"},{"issue":"8","key":"10.1016\/j.beha.2025.101602_bib19","doi-asserted-by":"crossref","first-page":"L530","DOI":"10.1152\/ajplung.00039.2013","article-title":"Cigarette smoke and CFTR: implications in the pathogenesis of COPD","volume":"305","author":"Rab","year":"2013","journal-title":"305, American Journal of Physiology - Lung Cellular and Molecular Physiology"},{"issue":"11","key":"10.1016\/j.beha.2025.101602_bib20","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1164\/rccm.201304-0733OC","article-title":"Cigarette smoke induces systemic defects in cystic fibrosis transmembrane conductance regulator function","volume":"188","author":"Raju","year":"2013","journal-title":"Am J Respir Crit Care Med [Internet]"},{"key":"10.1016\/j.beha.2025.101602_bib21","article-title":"Cystic fibrosis lung disease in the aging population","volume":"12","author":"K\u00fcnzi","year":"2021","journal-title":"Front Pharmacol [Internet]"},{"key":"10.1016\/j.beha.2025.101602_bib22","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3389\/fphar.2021.573065","article-title":"Enhancing cystic fibrosis immune regulation","volume":"12","author":"van Heeckeren","year":"2021","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.beha.2025.101602_bib23","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1002\/ppul.26898","article-title":"Effects of highly effective modulator therapy on the dynamics of the respiratory mucosal environment and inflammatory response in cystic fibrosis","volume":"59","author":"Atteih","year":"2024","journal-title":"Pediatr Pulmonol [Internet]"},{"key":"10.1016\/j.beha.2025.101602_bib24","first-page":"S4","article-title":"Rapid therapeutic advances in CFTR modulator science","volume":"53","author":"Clancy","year":"2018","journal-title":"Pediatr Pulmonol [Internet]"},{"key":"10.1016\/j.beha.2025.101602_bib25","article-title":"Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor-Ivacaftor","volume":"14","author":"T\u00fcmmler","year":"2023","journal-title":"Front Pharmacol [Internet]"},{"issue":"10","key":"10.1016\/j.beha.2025.101602_bib26","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1080\/17476348.2018.1512409","article-title":"Emerging pharmacotherapies in cystic fibrosis","volume":"12","author":"McElvaney","year":"2018","journal-title":"Expert Rev Respir Med [Internet]"},{"key":"10.1016\/j.beha.2025.101602_bib27","article-title":"CFTR correctors and antioxidants partially normalize lipid imbalance but not abnormal basal inflammatory cytokine profile in CF bronchial epithelial cells","volume":"12","author":"Veltman","year":"2021","journal-title":"Front Physiol [Internet]"},{"issue":"23","key":"10.1016\/j.beha.2025.101602_bib28","doi-asserted-by":"crossref","first-page":"7428","DOI":"10.3390\/jcm13237428","article-title":"A global perspetive on transition models for pediatric to adult cystic fibrosis care: what has been made so far?","volume":"13","author":"Poamangeagra","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.beha.2025.101602_bib29","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.pneumo.2018.09.012","article-title":"Ageing with cystic fibrosis: classical and emerging comorbidities in adults with cystic fibrosis","volume":"74","author":"Regard","year":"2018","journal-title":"Revue de Pneumologie Clinique. Elsevier Masson SAS"},{"key":"10.1016\/j.beha.2025.101602_bib30","doi-asserted-by":"crossref","first-page":"586","DOI":"10.3389\/fimmu.2018.00586","article-title":"Age and age-related diseases: role of inflammation triggers and cytokines","volume":"9","author":"Rea","year":"2018","journal-title":"Front Immunol [Internet]"},{"key":"10.1016\/j.beha.2025.101602_bib31","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/cei.12836","article-title":"Intracellular signalling pathways: targets to reverse immunosenescence","volume":"187","author":"Fulop","year":"2017","journal-title":"Clinical and Experimental Immunology. Blackwell Publishing Ltd"},{"key":"10.1016\/j.beha.2025.101602_bib32","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/cei.12881","article-title":"Innate immune responses in the ageing lung [Internet]","volume":"187","author":"Boe","year":"2017","journal-title":"Clinical and Experimental Immunology. Blackwell Publishing Ltd"},{"issue":"5","key":"10.1016\/j.beha.2025.101602_bib33","article-title":"Treatment of pulmonary disease of cystic fibrosis: a comprehensive review","volume":"10","author":"Gir\u00f3n Moreno","year":"2021","journal-title":"Antibiot (Basel, Switzerland) [Internet]"},{"issue":"10","key":"10.1016\/j.beha.2025.101602_bib34","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.3390\/cells10102793","article-title":"Therapeutic approaches for patients with cystic fibrosis not eligible for current CFTR modulators","volume":"10","author":"Fajac","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.beha.2025.101602_bib35","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.tips.2020.06.009","article-title":"Mesenchymal stem cell immunomodulation: mechanisms and therapeutic potential","volume":"41","author":"Song","year":"2020","journal-title":"Trends in Pharmacological Sciences. Elsevier Ltd"},{"key":"10.1016\/j.beha.2025.101602_bib36","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.3389\/fimmu.2013.00201","article-title":"Mesenchymal stem cells in tissue repair","volume":"4","author":"Dimarino","year":"2013","journal-title":"Front Immunol"},{"key":"10.1016\/j.beha.2025.101602_bib37","article-title":"Emerging therapeutic potential of mesenchymal stem cell-derived extracellular vesicles in chronic respiratory diseases: an overview of recent progress","volume":"10","author":"Ma","year":"2022","journal-title":"Frontiers in Bioengineering and Biotechnology. Frontiers Media S.A"},{"issue":"8","key":"10.1016\/j.beha.2025.101602_bib38","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3389\/fbioe.2020.00148","article-title":"Five decades later, are mesenchymal stem cells still relevant? Vol. 8","author":"Gomez-Salazar","year":"2020","journal-title":"Frontiers in Bioengineering and Biotechnology. Frontiers Media S.A"},{"issue":"1","key":"10.1016\/j.beha.2025.101602_bib39","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13287-024-03722-3","article-title":"The potency of mesenchymal stem\/stromal cells: does donor sex matter? Vol. 15","volume":"15","author":"Maged","year":"2024","journal-title":"Stem Cell Research and Therapy. BioMed Central Ltd"},{"issue":"6","key":"10.1016\/j.beha.2025.101602_bib40","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1002\/sctm.17-0051","article-title":"Mesenchymal stem cells: time to change the name","volume":"6","author":"Caplan","year":"2017","journal-title":"Stem Cells Transl Med [Internet]"},{"key":"10.1016\/j.beha.2025.101602_bib41","article-title":"The macrophage response is driven by mesenchymal stem cell-mediated metabolic reprogramming [internet]","volume":"12","author":"Luque-Campos","year":"2021","journal-title":"Frontiers in Immunology. Frontiers Media S.A"},{"issue":"4","key":"10.1016\/j.beha.2025.101602_bib42","doi-asserted-by":"crossref","first-page":"375","DOI":"10.4252\/wjsc.v16.i4.375","article-title":"Interplay between mesenchymal stem cells and macrophages: promoting bone tissue repair","volume":"16","author":"Zhang","year":"2024","journal-title":"World J Stem Cells [Internet]"},{"issue":"4","key":"10.1016\/j.beha.2025.101602_bib43","article-title":"Key role of mesenchymal stromal cell interaction with macrophages in promoting repair of lung injury","volume":"24","author":"Jerkic","year":"2023","journal-title":"Int J Mol Sci [Internet]"},{"key":"10.1016\/j.beha.2025.101602_bib44","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/stem.3380","article-title":"Macrophages at the nexus of mesenchymal stromal cell potency: the emerging role of chemokine cooperativity","volume":"39","author":"Galipeau","year":"2021","journal-title":"Stem Cell"},{"issue":"11","key":"10.1016\/j.beha.2025.101602_bib45","first-page":"1","article-title":"Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine","volume":"45","author":"Murphy","year":"2013","journal-title":"Exp Mol Med [Internet]"},{"issue":"5","key":"10.1016\/j.beha.2025.101602_bib46","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jcyt.2020.11.007","article-title":"Mesenchymal stromal cell variables influencing clinical potency: the impact of viability, fitness, route of administration and host predisposition","volume":"23","author":"Galipeau","year":"2021","journal-title":"Cytotherapy"},{"key":"10.1016\/j.beha.2025.101602_bib47","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.yexcr.2013.04.004","article-title":"Growth, differentiation capacity, and function of mesenchymal stem cells expanded in serum-free medium developed via combinatorial screening","volume":"319","author":"Crapnell","year":"2013","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.beha.2025.101602_bib48","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.exphem.2006.07.014","article-title":"Isolation of human marrow-derived mesenchymal stem cells","volume":"34","author":"Lennon","year":"2006","journal-title":"Exp Hematol"},{"issue":"23\u201324","key":"10.1016\/j.beha.2025.101602_bib49","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1089\/ten.tea.2018.0126","article-title":"Human and rat bone marrow-derived mesenchymal stem cells differ in their response to fibroblast growth factor and platelet-derived growth factor","volume":"24","author":"Lennon","year":"2018","journal-title":"Tissue Eng"},{"key":"10.1016\/j.beha.2025.101602_bib50","article-title":"The changing epigenetic landscape of Mesenchymal Stem\/Stromal Cells during aging","volume":"137","author":"Cakouros","year":"2020","journal-title":"Bone [Internet]"},{"issue":"3","key":"10.1016\/j.beha.2025.101602_bib51","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/stem.3317","article-title":"FZD5 regulates cellular senescence in human mesenchymal stem\/stromal cells","volume":"39","author":"Harada","year":"2021","journal-title":"Stem Cell"},{"issue":"1","key":"10.1016\/j.beha.2025.101602_bib52","volume":"9","author":"Amati","year":"2018","journal-title":"Stem Cell Res Ther [Internet]"},{"issue":"46","key":"10.1016\/j.beha.2025.101602_bib53","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1016\/j.vaccine.2013.09.026","article-title":"Genetic variants within the MHC region are associated with immune responsiveness to childhood vaccinations","volume":"31","author":"Yucesoy","year":"2013","journal-title":"Vaccine [Internet]"},{"issue":"5","key":"10.1016\/j.beha.2025.101602_bib54","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2005.02.001","article-title":"Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients","volume":"11","author":"Lazarus","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.beha.2025.101602_bib55","first-page":"192","article-title":"Mesenchymal stem\/stromal cells as a valuable source for the treatment of immune-mediated disorders. Vol. 12, Stem Cell Research and Therapy","volume":"12","author":"Markov","year":"2021","journal-title":"BioMed Central Ltd"},{"key":"10.1016\/j.beha.2025.101602_bib56","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.04149-2020","article-title":"Healthy versus inflamed lung environments differentially effect MSCs","author":"Rolandsson","year":"2021","journal-title":"Eur Respir J [Internet]"},{"issue":"6","key":"10.1016\/j.beha.2025.101602_bib57","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1089\/ten.teb.2017.0093","article-title":"Efficacy of humanized mesenchymal stem cell cultures for bone tissue engineering: a systematic review with a focus on platelet derivatives","volume":"23","author":"Shanbhag","year":"2017","journal-title":"Tissue Eng Part B Rev [Internet]"},{"key":"10.1016\/j.beha.2025.101602_bib58","first-page":"114","article-title":"Strategies to address mesenchymal stem\/stromal cell heterogeneity in immunomodulatory profiles to improve cell-based therapies. Vol. 133, Acta Biomaterialia","author":"Dunn","year":"2021","journal-title":"Acta Mater"},{"key":"10.1016\/j.beha.2025.101602_bib59","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1007\/s00018-020-03454-6","article-title":"Mechanisms underlying the protective effects of mesenchymal stem cell-based therapy","volume":"77","author":"Fan","year":"2020","journal-title":"Cellular and Molecular Life Sciences. Springer"},{"issue":"1","key":"10.1016\/j.beha.2025.101602_bib60","first-page":"218","article-title":"Therapeutic potential of products derived from mesenchymal stem\/stromal cells in pulmonary disease","volume":"19","author":"Mohammadipoor","year":"2018","journal-title":"19, Respiratory Research. BioMed Central Ltd."},{"issue":"2","key":"10.1016\/j.beha.2025.101602_bib61","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3390\/ph16020220","article-title":"Human mesenchymal stem cell (hMSC) donor potency selection for the \u201cfirst in cystic fibrosis\u201d phase I clinical trial (CEASE-CF)","volume":"16","author":"Bonfield","year":"2023","journal-title":"Pharmaceuticals [Internet]"},{"issue":"8","key":"10.1016\/j.beha.2025.101602_bib62","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/sctm.20-0521","article-title":"Donor-defined mesenchymal stem cell antimicrobial potency against nontuberculous mycobacterium","volume":"10","author":"Bonfield","year":"2021","journal-title":"Stem Cells Transl Med"},{"issue":"2","key":"10.1016\/j.beha.2025.101602_bib63","doi-asserted-by":"crossref","first-page":"539","DOI":"10.5966\/sctm.2015-0427","article-title":"Concise review: mesenchymal stem cell therapy for pediatric disease: perspectives on success and potential improvements","volume":"6","author":"Nitkin","year":"2017","journal-title":"Stem Cells Transl Med"},{"issue":"9","key":"10.1016\/j.beha.2025.101602_bib64","article-title":"Mesenchymal stem cell soluble mediators and cystic fibrosis","volume":"7","author":"Sutton","year":"2017","journal-title":"J Stem Cell Res Ther [Internet]"},{"key":"10.1016\/j.beha.2025.101602_bib65","article-title":"Mesenchymal stem cell-based immunomodulation: properties and clinical application","volume":"2018","author":"Wang","year":"2018","journal-title":"Stem Cells International. Hindawi Limited"},{"issue":"6","key":"10.1016\/j.beha.2025.101602_bib66","doi-asserted-by":"crossref","first-page":"L908","DOI":"10.1152\/ajplung.00218.2020","article-title":"Differential effects of the cystic fibrosis lung inflammatory environment on mesenchymal stromal cells","volume":"319","author":"Abreu","year":"2020","journal-title":"Am J Physiol - Lung Cell Mol Physiol [Internet]"},{"key":"10.1016\/j.beha.2025.101602_bib67","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.imlet.2019.12.011","article-title":"Immunoregulatory properties of mesenchymal stem cells: micro-RNAs","volume":"219","author":"Rostami","year":"2020","journal-title":"Immunology Letters. Elsevier B.V."},{"issue":"9","key":"10.1016\/j.beha.2025.101602_bib68","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.3390\/cells9092142","article-title":"Human mesenchymal stromal cell secretome promotes the immunoregulatory phenotype and phagocytosis activity in human macrophages","volume":"9","author":"Holopainen","year":"2020","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.beha.2025.101602_bib69","first-page":"557","article-title":"Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use","volume":"16","author":"Lazarus","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.beha.2025.101602_bib70","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1200\/JCO.2000.18.2.307","article-title":"Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy","volume":"18","author":"Ko\u00e7","year":"2000","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2025.101602_bib71","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S2213-2600(14)70291-7","article-title":"Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial","volume":"3","author":"Wilson","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.beha.2025.101602_bib72","doi-asserted-by":"crossref","first-page":"539","DOI":"10.5966\/sctm.2015-0427","article-title":"Concise review: mesenchymal stem cell therapy for pediatric disease: perspectives on success and potential improvements","volume":"6","author":"Nitkin","year":"2017","journal-title":"Stem Cells Transl Med"},{"issue":"4","key":"10.1016\/j.beha.2025.101602_bib73","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1165\/rcmb.2019-0286ST","article-title":"Stem cells, cell therapies, and bioengineering in lung biology and diseases 2017","volume":"61","author":"Ryan","year":"2019","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"4","key":"10.1016\/j.beha.2025.101602_bib74","first-page":"1","article-title":"Stem cells, cell therapies, and bioengineering in lung biology and disease 2019","volume":"6","author":"Wagner","year":"2020","journal-title":"ERJ Open Res [Internet]"},{"key":"10.1016\/j.beha.2025.101602_bib75","first-page":"355","article-title":"A review and update for registered clinical studies of stem cells for non-tumorous and non-hematological diseases","volume":"18","author":"Chen","year":"2021","journal-title":"Regenerative Therapy. Japanese Society of Regenerative Medicine"},{"issue":"11","key":"10.1016\/j.beha.2025.101602_bib76","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/sctm.18-0074","article-title":"Cell-based therapies: the nonresponder","volume":"7","author":"Caplan","year":"2018","journal-title":"Stem Cells Transl Med [Internet]"},{"issue":"5","key":"10.1016\/j.beha.2025.101602_bib77","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.bbmt.2020.01.018","article-title":"A phase 3, single-arm, prospective study of remestemcel-L, ex vivo culture-expanded adult human mesenchymal stromal cells for the treatment of pediatric patients who failed to respond to steroid treatment for acute graft-versus-host disease","volume":"26","author":"Kurtzberg","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.beha.2025.101602_bib78","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.bbmt.2020.01.026","article-title":"Study 275: updated expanded access program for remestemcel-L in steroid-refractory acute graft-versus-host disease in children","volume":"26","author":"Kurtzberg","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2025.101602_bib79","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/sctm.20-0521","article-title":"Donor\u2010defined mesenchymal stem cell antimicrobial potency against nontuberculous mycobacterium","volume":"10","author":"Bonfield","year":"2021","journal-title":"Stem Cells Transl Med"},{"key":"10.1016\/j.beha.2025.101602_bib80","article-title":"Antimicrobial properties of mesenchymal stem cells: therapeutic potential for cystic fibrosis infection, and treatment","volume":"2016","author":"Sutton","year":"2016","journal-title":"Stem Cell Int"},{"issue":"2","key":"10.1016\/j.beha.2025.101602_bib81","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/acr2.11356","article-title":"Optimization of human mesenchymal stem cells for rheumatoid arthritis: implications for improved therapeutic outcomes","volume":"4","author":"Breitman","year":"2022","journal-title":"ACR Open Rheumatol"},{"issue":"No 2","key":"10.1016\/j.beha.2025.101602_bib82","doi-asserted-by":"crossref","DOI":"10.4236\/scd.2013.32019","article-title":"Cell based therapy aides in infection and inflammation resolution in the murine model of cystic fibrosis lung disease","volume":"3","author":"Bonfield","year":"2013","journal-title":"Stem Cell Discov"},{"issue":"6","key":"10.1016\/j.beha.2025.101602_bib83","doi-asserted-by":"crossref","first-page":"L823","DOI":"10.1152\/ajplung.00263.2019","article-title":"Lung inflammatory environments differentially alter mesenchymal stromal cell behavior","volume":"317","author":"Abreu","year":"2019","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.beha.2025.101602_bib84","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/jcb.20886","article-title":"Mesenchymal stem cells as trophic mediators","volume":"98","author":"Caplan","year":"2006","journal-title":"J Cell Biochem"},{"issue":"1","key":"10.1016\/j.beha.2025.101602_bib85","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.stem.2011.06.008","article-title":"The MSC: an injury drugstore","volume":"9","author":"Caplan","year":"2011","journal-title":"Cell Stem Cell [Internet]"},{"issue":"9","key":"10.1016\/j.beha.2025.101602_bib86","doi-asserted-by":"crossref","DOI":"10.4172\/2157-7633.1000400","article-title":"Mesenchymal stem cell soluble mediators and cystic fibrosis","volume":"7","author":"Sutton","year":"2017","journal-title":"J Stem Cell Res Ther"},{"issue":"4","key":"10.1016\/j.beha.2025.101602_bib87","article-title":"Mesenchymal stromal cells: an antimicrobial and host-directed therapy for complex infectious diseases. Vol. 34","volume":"34","author":"Shaw","year":"2021","journal-title":"Clinical Microbiology Reviews. American Society for Microbiology"},{"issue":"3","key":"10.1016\/j.beha.2025.101602_bib88","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/stem.2948","article-title":"Concise review: exploring immunomodulatory features of mesenchymal stromal cells in humanized mouse models","volume":"37","author":"Mehler","year":"2019","journal-title":"Stem Cells [Internet]"},{"key":"10.1016\/j.beha.2025.101602_bib89","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.7150\/thno.46436","article-title":"Application of mesenchymal stem cell therapy for aging frailty: from mechanisms to therapeutics","volume":"11","author":"Zhu","year":"2021","journal-title":"Theranostics. Ivyspring International Publisher"},{"issue":"17","key":"10.1016\/j.beha.2025.101602_bib90","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1007\/s00018-019-03125-1","article-title":"Biological functions of mesenchymal stem cells and clinical implications","volume":"76","author":"Naji","year":"2019","journal-title":"Cell Mol Life Sci [Internet]"},{"issue":"4","key":"10.1016\/j.beha.2025.101602_bib91","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/1352458517703802","article-title":"Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis","volume":"24","author":"Cohen","year":"2018","journal-title":"Mult Scler J"},{"issue":"1","key":"10.1016\/j.beha.2025.101602_bib92","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/ALN.0000000000003018","article-title":"Human umbilical cord mesenchymal stromal cells attenuate systemic sepsis in part by enhancing peritoneal macrophage bacterial killing via heme oxygenase-1 induction in rats","volume":"132","author":"Jerkic","year":"2020","journal-title":"Anesthesiology"},{"key":"10.1016\/j.beha.2025.101602_bib93","first-page":"1","article-title":"Dysfunctional inflammation in cystic fibrosis airways: from mechanisms to novel therapeutic approaches","volume":"22","author":"Ghigo","year":"2021","journal-title":"International Journal of Molecular Sciences. MDPI AG"},{"issue":"2","key":"10.1016\/j.beha.2025.101602_bib94","doi-asserted-by":"crossref","first-page":"37","DOI":"10.62347\/JAWM2040","article-title":"El-Hashash, Mesenchymal stromal cell-based therapy in lung diseases; from resarch to clinic","volume":"13","author":"Yuan","year":"2024","journal-title":"Am J Stem Cells"},{"issue":"9","key":"10.1016\/j.beha.2025.101602_bib95","article-title":"Human mesenchymal stromal cell secretome promotes the immunoregulatory phenotype and phagocytosis activity in human macrophages","volume":"9","author":"Holopainen","year":"2020","journal-title":"Cells [Internet]"},{"issue":"3","key":"10.1016\/j.beha.2025.101602_bib96","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jcf.2022.12.001","article-title":"A phase I study assessing the safety and tolerability of allogeneic mesenchymal stem cell infusion in adults with cystic fibrosis","volume":"22","author":"Roesch","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"8","key":"10.1016\/j.beha.2025.101602_bib97","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/thorax-2023-220819","article-title":"Human mesenchymal stromal cells inhibit Mycobacterium avium replication in clinical relevant models of lung infection","volume":"79","author":"Shaw","year":"2024","journal-title":"Thorax"},{"key":"10.1016\/j.beha.2025.101602_bib98","doi-asserted-by":"crossref","DOI":"10.1152\/ajplung.00182.2009","article-title":"Human mesenchymal stem cells suppress chronic airway inflammation in the murine ovalbumin asthma model","volume":"299","author":"Bonfield","year":"2010","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"1","key":"10.1016\/j.beha.2025.101602_bib99","first-page":"20","article-title":"Lights and shadows in the use of mesenchymal stem cells in lung inflammation, a poorly investigated topic in cystic fibrosis","volume":"9","author":"Caretti","year":"2019","journal-title":"9, Cells. NLM (Medline)"},{"key":"10.1016\/j.beha.2025.101602_bib100","article-title":"Dissecting the role of mesenchymal stem cells in idiopathic pulmonary fibrosis: cause or solution [internet]","volume":"12","author":"Samarelli","year":"2021","journal-title":"Frontiers in Pharmacology. Frontiers Media S.A"},{"issue":"4","key":"10.1016\/j.beha.2025.101602_bib101","first-page":"1","article-title":"Therapeutic features and updated clinical trials of mesenchymal stem cell (Msc)-derived exosomes. Vol. 10","volume":"10","author":"Lee","year":"2021","journal-title":"Journal of Clinical Medicine. MDPI"},{"issue":"2","key":"10.1016\/j.beha.2025.101602_bib102","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00018-020-03600-0","article-title":"Functional heterogeneity of mesenchymal stem cells from natural niches to culture conditions: implications for further clinical uses","volume":"78","author":"Costa","year":"2021","journal-title":"Cell Mol Life Sci [Internet]"},{"key":"10.1016\/j.beha.2025.101602_bib103","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.575488","article-title":"Integrated analysis of transcriptome and secretome from umbilical cord mesenchymal stromal cells reveal new mechanisms for the modulation of inflammation and immune activation","volume":"11","author":"Cruz-Barrera","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.beha.2025.101602_bib104","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s12931-018-0921-x","article-title":"Therapeutic potential of products derived from mesenchymal stem\/stromal cells in pulmonary disease","volume":"19","author":"Mohammadipoor","year":"2018","journal-title":"Respir Res [Internet]"},{"issue":"7","key":"10.1016\/j.beha.2025.101602_bib105","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.3390\/ijms22073576","article-title":"Mesenchymal stem cells as a cornerstone in a galaxy of intercellular signals: basis for a new era of medicine","volume":"22","author":"Fern\u00e1ndez-Francos","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.beha.2025.101602_bib106","doi-asserted-by":"crossref","first-page":"482","DOI":"10.2174\/1574888X14666190228103230","article-title":"Emerging role of mesenchymal stem cell-derived exosomes in regenerative medicine","volume":"14","author":"Zhao","year":"2019","journal-title":"Curr Stem Cell Res Ther"},{"key":"10.1016\/j.beha.2025.101602_bib107","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.3389\/fimmu.2020.01338","article-title":"Mesenchymal stromal cells for graft versus host disease: mechanism-based biomarkers","volume":"11","author":"Cheung","year":"2020","journal-title":"Front Immunol [Internet]"},{"issue":"11","key":"10.1016\/j.beha.2025.101602_bib108","doi-asserted-by":"crossref","first-page":"11899","DOI":"10.18632\/oncotarget.7727","volume":"7","author":"Golpanian","year":"2016","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.beha.2025.101602_bib109","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/stem.2288","article-title":"Knockdown of DNMT1 and DNMT3a promotes the angiogenesis of human mesenchymal stem cells leading to arterial specific differentiation","volume":"34","author":"Zhang","year":"2016","journal-title":"Stem Cells [Internet]"},{"issue":"1","key":"10.1016\/j.beha.2025.101602_bib110","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s13287-018-1031-x","article-title":"LincRNA-p21 promotes mesenchymal stem cell migration capacity and survival through hypoxic preconditioning","volume":"9","author":"Meng","year":"2018","journal-title":"Stem Cell Res Ther"},{"issue":"5","key":"10.1016\/j.beha.2025.101602_bib111","doi-asserted-by":"crossref","first-page":"7301","DOI":"10.1002\/jcp.27488","article-title":"Mesenchymal stem cells overexpressing heme oxygenase-1 ameliorate lipopolysaccharide-induced acute lung injury in rats","volume":"234","author":"Chen","year":"2019","journal-title":"J Cell Physiol"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692625000076?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692625000076?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T07:29:25Z","timestamp":1777793365000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692625000076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":111,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1521692625000076"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2025.101602","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Human mesenchymal stem cell therapy: Potential advances for reducing cystic fibrosis infection and organ inflammation","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2025.101602","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101602"}}